Once again brown-nosed pumping lunatic, head up her
gluteusmaximus chimes in with more falsified information.
Maybe it's Johnny babyboy Meilink's broker hoping to salvage
his BSX position for his loser client? LOL
>>Boston Scientific has seen steady turnover in its management
team, been in court multiple times for patent infringement
hearings, been the subject of several Department of Justice
investigations, had to conduct a massive recall of its
defibrillators in 2010, racked up $5 billion in litigation
charges in the past five years and hasn't turned a profit
Despite that tale of woe, optimistic investors started
snapping up shares in recent months, pushing the stock up
nearly 50% since Labor Day. Yet this is still a very
troubled company, carrying about $5 billion in debt. To
boost growth, Boston Scientific is making acquisitions to
bring fresh growth opportunities. Yet some of those deals,
such as the one for a heart-valve business, merely
represent second-tier offerings in crowded fields.
At a November 2010 meeting with analysts, management ran
through a series of steps that intend to boost profits 10%
annually, highlighted by cost cuts. But most analysts
scoffed at management's targets. Goldman Sachs doubts that
cost-cutting will lead the company out of its morass: "Given
our below consensus revenue estimates for the foreseeable
future, we believe these cost controls will essentially be
an offset for lower-than-expected revenue growth rather than
incremental growth opportunities." They predict shares will
fall back to $6, nearly 20% below current levels.
Citigroup put the outlook in even harsher terms: "BSX
currently has 75% of sales in markets that are collectively
declining and are expected to be flat over the next three
years....(and) a thin pipeline and cost cutting plans don't
mesh with a viable plan to grow sales."<<
You are wrong on everything, BSX is number one in all the device markets they compete in, and they are growing in double digits in everything, while the competitors are going down in flames with shoddy products and FDA problems. You must be a loser BSX employee who was fired for poor performance and now you're jealous you can't share in the success of the company. ABT's bio-crap stent is a fraud, FDA will put an end to that nonsense very soon. Go BSX!!!
The JPM presentation is up at the webcast link (BSX).
Mr. Elliott sounds quite confident and pregnant with news.
But I again advise caution on CALLS. The news may be a basket of acquisitions, which might weigh on the sp.
I can't tell if you're joking or delusional.
BSX is third in ICDs, and their stent market share is eroding. European stent sales will probably face intense pressure from Abbott's bioabsorbable stent.
As far as sales force, which sales force is doing the wiping? This weeks sales force or last week? Turnover in their CRV sales force is the worst in the industry. One could surmise from the poor product cadence that their engineering turnover isn't much better.
I wouldn't tout reliability and quality as a sales point either unless you have the memory of a goldfish.
8 bucks isn't exactly a bold call either. What BSX isn't doing well is growing the top-line but it is improving the bottom line largely be reducing employee compensation and number. While this does improve the financials in the short term, it does not bode well for the long term viability of the company.
BSX needs to get new ICDs, competitive leads to go with them, and new stents to the market quickly if it's going to remain relative to the industry.
Agreed, BSX is going to soar well past $8 next week. Shorts are going to get vaporized. Earnings are coming out soon, and they will once again confirm BSX's near-monopoly on cardiac devices, stents and ICDs. STJ, MDT, JNJ, and ABT have been wiped off the map by BSX's hard-working sales force. Only BSX has the best products, nobody else even comes close to BSX's bulletproof reliability and quality.